Chemotherapy News and Research

Latest Chemotherapy News and Research

New breast cancer biomarker may help identify women's response to tamoxifen

Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy.

19 May 2011

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Biothera began dosing patients today in a Phase III trial evaluating Imprime PGG in combination with cetuximab as a potential new treatment for recurrent or progressive KRAS wild-type colorectal cancer.

19 May 2011

Clinical PET system for early stage breast cancer diagnosis

European researchers have developed a clinical PET system with the highest resolution and sensitivity in the market, specifically dedicated to breast cancer detection in early stages.

18 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Micromet, Inc. today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive acute lymphoblastic leukemia were published in the May 16th on-line edition of the Journal of Clinical Oncology.

18 May 2011

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

Cytheris SA and the Cancer Immunotherapy Trials Network, a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center headquartered at Fred Hutchinson Cancer Research Center, Seattle, Washington, today announced the selection of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, as one of the first immunotherapeutic agents proposed for initial clinical trials at network institutions.

18 May 2011

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

The anti-inflammatory drug celecoxib, known by the brand name Celebrex, triggers liver cancer cell death by reacting with a protein in a way that makes those cells commit suicide, according to a new study.

17 May 2011

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Updated data from a National Cancer Institute-sponsored clinical trial conducted by the Cancer and Leukemia Group (CALGB) was presented May 5 at the 13th International Myeloma Workshop in Paris, France.

16 May 2011

Researchers untangle two distinct ways in which tumor-suppressor protein works

Researchers at the Stanford University School of Medicine have untangled two distinct ways in which a common, naturally occurring "tumor-suppressor" protein works.

13 May 2011

Rethink praises Ontario's decision to provide breast cancer patients with access to Herceptin

Today, Rethink Breast Cancer (Rethink) applauds the Ontario government's decision to provide breast cancer patients with tumours less than or equal to 1 cm access to the revolutionary drug Herceptin under the new Evidence Building Program.

13 May 2011

Study: OVA1 blood test can accurately predict ovarian cancer in women with pelvic masses

A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of Obstetrics and Gynecology guidelines for determining the likelihood that an ovarian mass is cancerous prior to surgery would accurately identify more women with ovarian cancer if the OVA1 blood test were used in place of the currently recommended CA 125 blood test.

From Quest Diagnostics 13 May 2011

Coffee provides protections from a type of breast cancer: Study

For the study they compared coffee consumption in postmenopausal women with breast cancer and women of the same age without cancer, they found those who drank five or more cups of java a day showed a 0.43 times lower risk of estrogen-receptor negative cancers. Around one in four women diagnosed with breast cancer will have estrogen-receptor negative breast cancer, which is often resilient to drug treatment and requires intensive chemotherapy.

12 May 2011

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, presented new clinical and pre-clinical data related to the safety and efficacy of its novel, lead defensin-mimetic antibiotic, PMX-30063.

12 May 2011

Health Canada approves EMEND IV formulation to prevent chemotherapy-induced nausea, vomiting

Today Merck announced that Health Canada has approved the new intravenous formulation of EMEND IV. Used in combination with a 5-HT3 antagonist class of antiemetics and dexamethasone, fosaprepitant dimeglumine is indicated for the prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy.

12 May 2011

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.

12 May 2011

Reprogrammed herpes virus can improve early cancer diagnosis

Scientists have used a genetically re-engineered herpes virus that selectively hunts down and infects cancerous tumors and then delivers genetic material that prompts cancers to secrete a biomarker and reveal their presence.

12 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

Women with invasive breast cancer can benefit from new genomic test

A new genomic test combining multiple signatures - a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity - shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center.

11 May 2011

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the company submitted a New Drug Application for vemurafenib to the U.S. Food and Drug Administration for people with BRAF V600 mutation-positive metastatic melanoma, and that Roche submitted a Marketing Authorization Application to the European Medicines Agency for vemurafenib in the same indication.

11 May 2011

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Sosei Group Corporation, the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc (miconazole Lauriad) in Japan from BioAlliance Pharma.

11 May 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

New breast cancer biomarker may help identify women's response to tamoxifen

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Clinical PET system for early stage breast cancer diagnosis

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Researchers untangle two distinct ways in which tumor-suppressor protein works

Rethink praises Ontario's decision to provide breast cancer patients with access to Herceptin

Study: OVA1 blood test can accurately predict ovarian cancer in women with pelvic masses

Coffee provides protections from a type of breast cancer: Study

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

Health Canada approves EMEND IV formulation to prevent chemotherapy-induced nausea, vomiting

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Reprogrammed herpes virus can improve early cancer diagnosis

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Women with invasive breast cancer can benefit from new genomic test

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in